

# Neda Rasouli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7788554/publications.pdf>

Version: 2024-02-01

86  
papers

6,557  
citations

76196

40  
h-index

62479

80  
g-index

87  
all docs

87  
docs citations

87  
times ranked

9482  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 230-240.	1.8	24
2	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished $\beta$ -Cell Function in Patients With Type 2 Diabetes in the GRADE Study. <i>Diabetes</i> , 2022, 71, 1261-1271.	0.3	11
3	Response to Letter to the Editor from Chang Villacreses et al: "Effects of vitamin D supplementation on insulin sensitivity and secretion in prediabetes." <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	0
4	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. <i>Diabetes Care</i> , 2022, 45, 1670-1690.	4.3	109
5	Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107733.	1.2	12
6	Association of Baseline Characteristics With Insulin Sensitivity and $\beta$ -Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021, 44, 340-349.	4.3	16
7	Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2767-2778.	1.8	20
8	Association of glycemia with insulin sensitivity and $\beta$ -cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107912.	1.2	5
9	Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1201-1209.	2.2	9
10	Shape of the OGTT glucose response curve: relationship with $\beta$ -cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002264.	1.2	12
11	Should metformin remain the first-line therapy for treatment of type 2 diabetes?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882098022.	1.4	58
12	Serum lipid profile as a tool to predict incident diabetes: Is it a wishful thinking?. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107755.	1.2	3
13	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. <i>Diabetes Care</i> , 2020, 43, 940-947.	4.3	14
14	An Escape From Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3460-e3461.	1.8	2
15	Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e130-e138.	1.8	22
16	Reproducibility of a prediabetes classification in a contemporary population. <i>Metabolism Open</i> , 2020, 6, 100031.	1.4	6
17	Hyperoxia improves carbohydrate metabolism by browning of white adipocytes in obese type 2 diabetic rats. <i>Life Sciences</i> , 2019, 220, 58-68.	2.0	5
18	Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 520-530.	13.9	423

#	ARTICLE	IF	CITATIONS
19	Glycaemic efficacy and safety of linagliptin compared to a basalâ€bolus insulin regimen in patients with type 2 diabetes undergoing nonâ€cardiac surgery: A multicentre randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 837-843.	2.2	53
20	The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of insulin resistance, Î²-cell function, and diabetes in Hispanics and African Americans. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 118-122.	1.2	71
21	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. <i>Drugs</i> , 2018, 78, 203-214.	4.9	5
22	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018, 41, 2552-2559.	4.3	177
23	Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. <i>Diabetes Care</i> , 2018, 41, 1590-1599.	4.3	16
24	Management of Hemoglobin Variants Detected Incidentally in HbA1c Testing: A Common Problem Currently Lacking a Standard Approach. <i>Diabetes Care</i> , 2017, 40, e8-e9.	4.3	10
25	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 864-876.	5.5	244
26	Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation. <i>Hormone and Metabolic Research</i> , 2017, 49, 50-57.	0.7	8
27	Impact of Glucose Management Team on Outcomes of Hospitalization in Patients With Type 2 Diabetes Admitted to the Medical Service. <i>Endocrine Practice</i> , 2016, 22, 1401-1405.	1.1	31
28	Adipose Tissue Hypoxia and Insulin Resistance. <i>Journal of Investigative Medicine</i> , 2016, 64, 830-832.	0.7	28
29	Endocrinology Telehealth Consultation Improved Glycemic Control Similar to Face-to-Face Visits in Veterans. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1079-1086.	1.3	25
30	Led Astray by Hemoglobin A1c. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2016, 4, 232470961662854.	0.3	3
31	Integrative mRNA-microRNA analyses reveal novel interactions related to insulin sensitivity in human adipose tissue. <i>Physiological Genomics</i> , 2016, 48, 145-153.	1.0	18
32	Adipose Tissue Hypoxia, Inflammation, and Fibrosis in Obese Insulin-Sensitive and Obese Insulin-Resistant Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1422-1428.	1.8	136
33	The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of Î²-cell function in African American women. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 561-565.	1.5	25
34	The Effects of Temperature and Seasons on Subcutaneous White Adipose Tissue in Humans. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 180-181.	0.2	2
35	Glycemic Control and Outcomes of Hospitalization in Noncritically Ill Patients With Type 2 Diabetes Admitted With Cardiac Problems or Infections. <i>Endocrine Practice</i> , 2014, 20, 1303-1308.	1.1	6
36	Professional Practice Committee. <i>Diabetes Care</i> , 2014, 37, S1-S1.	4.3	16

#	ARTICLE	IF	CITATIONS
37	Effect of Glargine Insulin Delivery Method (Pen Device Versus Vial/Syringe) on Glycemic Control and Patient Preferences in Patients with Type 1 and Type 2 Diabetes. <i>Endocrine Practice</i> , 2014, 20, 536-539.	1.1	14
38	The Effects of Temperature and Seasons on Subcutaneous White Adipose Tissue in Humans: Evidence for Thermogenic Gene Induction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2772-E2779.	1.8	83
39	Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity. <i>PLoS ONE</i> , 2014, 9, e102190.	1.1	45
40	Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action. <i>Diabetes Care</i> , 2013, 36, 1807-1814.	4.3	134
41	An ACACB Variant Implicated in Diabetic Nephropathy Associates with Body Mass Index and Gene Expression in Obese Subjects. <i>PLoS ONE</i> , 2013, 8, e56193.	1.1	11
42	Subcutaneous Administration of Glargine to Diabetic Patients Receiving Insulin Infusion Prevents Rebound Hyperglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3132-3137.	1.8	81
43	Cystic Fibrosis-Related Diabetes in Adults: Inpatient Management of 121 Patients during 410 Admissions. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 1038-1044.	1.3	18
44	Improved insulin sensitivity after treatment with PPAR $\gamma$ 3 and PPAR $\gamma$ 1 ligands is mediated by genetically modulated transcripts. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 484-497.	0.7	24
45	Genetic Risk Factors for Type 2 Diabetes: A Trans-Regulatory Genetic Architecture?. <i>American Journal of Human Genetics</i> , 2012, 91, 466-477.	2.6	31
46	Regulation of Small Ubiquitin-Like Modifier-1, Nuclear Receptor Coreceptor, Histone Deacetylase 3, and Peroxisome Proliferator-Activated Receptor-1 $\beta$ in Human Adipose Tissue. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 312-317.	0.5	2
47	DHA reduces the atrophy-associated Fn14 protein in differentiated myotubes during coculture with macrophages. <i>Journal of Nutritional Biochemistry</i> , 2012, 23, 885-891.	1.9	9
48	Adipose triglyceride lipase expression in human adipose tissue and muscle. Role in insulin resistance and response to training and pioglitazone. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1012-1020.	1.5	49
49	Adipose Tissue Extracellular Matrix and Vascular Abnormalities in Obesity and Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1990-E1998.	1.8	226
50	Global Gene Expression Profiles of Subcutaneous Adipose and Muscle From Glucose-Tolerant, Insulin-Sensitive, and Insulin-Resistant Individuals Matched for BMI. <i>Diabetes</i> , 2011, 60, 1019-1029.	0.3	91
51	Comparison of 70/30 Biphasic Insulin With Glargine/Lispro Regimen in Non-critically Ill Diabetic Patients on Continuous Enteral Nutrition Therapy. <i>Nutrition in Clinical Practice</i> , 2011, 26, 714-717.	1.1	56
52	Matrix Metalloproteinase-9 Is Increased in Obese Subjects and Decreases in Response to Pioglitazone. <i>Molecular Endocrinology</i> , 2010, 24, 1106-1107.	3.7	2
53	Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E1016-E1027.	1.8	363
54	Matrix Metalloproteinase-9 Is Increased in Obese Subjects and Decreases in Response to Pioglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2993-3001.	1.8	70

#	ARTICLE	IF	CITATIONS
55	Insulin Resistance in African-American and Caucasian Women: Differences in Lipotoxicity, Adipokines, and Gene Expression in Adipose Tissue and Muscle. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4441-4448.	1.8	39
56	Association of Scavenger Receptors in Adipose Tissue With Insulin Resistance in Nondiabetic Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1328-1335.	1.1	51
57	Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E1300-E1310.	1.8	181
58	Adipocytokines and the Metabolic Complications of Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, s64-s73.	1.8	597
59	Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E393-E400.	1.8	50
60	Stearoyl-Coenzyme A Desaturase 1 Gene Expression Increases after Pioglitazone Treatment and Is Associated with Peroxisomal Proliferator-Activated Receptor- $\beta$ Responsiveness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4431-4439.	1.8	65
61	Calcium Is Involved in Formation of High Molecular Weight Adiponectin. <i>Metabolic Syndrome and Related Disorders</i> , 2008, 6, 103-111.	0.5	25
62	Thrombospondin-1 Is an Adipokine Associated With Obesity, Adipose Inflammation, and Insulin Resistance. <i>Diabetes</i> , 2008, 57, 432-439.	0.3	159
63	Endoplasmic Reticulum Stress Markers Are Associated with Obesity in Nondiabetic Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4532-4541.	1.8	243
64	Intermuscular lipid: a marker of disordered fat partitioning or the consequence of obesity?. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1585-1586.	2.2	6
65	Retinol Binding Protein 4 Expression in Humans: Relationship to Insulin Resistance, Inflammation, and Response to Pioglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2590-2597.	1.8	200
66	Human Visfatin Expression: Relationship to Insulin Sensitivity, Intramyocellular Lipids, and Inflammation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 666-672.	1.8	179
67	Impact of Family History of Diabetes and Ethnicity on $\beta$ -Cell Function in Obese, Glucose-Tolerant Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4656-4663.	1.8	29
68	Effects of pioglitazone and metformin on $\beta$ -cell function in nondiabetic subjects at high risk for type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E359-E365.	1.8	22
69	Ectopic fat accumulation and metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 1-10.	2.2	123
70	Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. <i>Diabetologia</i> , 2007, 50, 1621-1630.	2.9	91
71	A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. <i>Vascular Health and Risk Management</i> , 2007, 3, 967-73.	1.0	41
72	Oxidative stress in diabetes: A mechanistic overview of its effects on atherogenesis and myocardial dysfunction. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 794-803.	1.2	138

#	ARTICLE	IF	CITATIONS
73	The prevention and treatment of metabolic syndrome and high-risk obesity. <i>Current Opinion in Cardiology</i> , 2006, 21, 479-485.	0.8	23
74	Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E1100-E1105.	1.8	112
75	Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E42-E46.	1.8	102
76	OXPAT/PAT-1 Is a PPAR-Induced Lipid Droplet Protein That Promotes Fatty Acid Utilization. <i>Diabetes</i> , 2006, 55, 3418-3428.	0.3	276
77	Pioglitazone induces apoptosis of macrophages in human adipose tissue. <i>Journal of Lipid Research</i> , 2006, 47, 2080-2088.	2.0	63
78	The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. <i>Journal of Lipid Research</i> , 2006, 47, 2444-2450.	2.0	150
79	Lipin Expression Is Attenuated in Adipose Tissue of Insulin-Resistant Human Subjects and Increases With Peroxisome Proliferator-Activated Receptor $\alpha$ Activation. <i>Diabetes</i> , 2006, 55, 2811-2818.	0.3	97
80	Pathogenesis and Treatment of High-Risk Obesity. , 2006, , 48-63.		0
81	Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E930-E934.	1.8	123
82	Effects of Short-Term Experimental Insulin Resistance and Family History of Diabetes on Pancreatic $\beta$ -Cell Function in Nondiabetic Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5825-5833.	1.8	25
83	Expression of CD68 and Macrophage Chemoattractant Protein-1 Genes in Human Adipose and Muscle Tissues: Association With Cytokine Expression, Insulin Resistance, and Reduction by Pioglitazone. <i>Diabetes</i> , 2005, 54, 2305-2313.	0.3	331
84	Improved Glycemic Control in Subjects with Atypical Diabetes Results from Restored Insulin Secretion, But Not Improved Insulin Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6331-6335.	1.8	16
85	Divergent Effects of Peroxisome Proliferator-activated Receptor $\beta$ Agonists and Tumor Necrosis Factor $\alpha$ on Adipocyte ApoE Expression. <i>Journal of Biological Chemistry</i> , 2004, 279, 47626-47632.	1.6	58
86	Peroxisome Proliferator-Activated Receptor Ligands as Antiatherogenic Agents: Panacea or Another Pandora's Box?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 1-8.	1.0	8